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Abstract
Background: Despite the important implications of lipohypertrophy for diabetes control, there is a dearth of
information and research about the subject in children. The aim of this study was to study the prevalence of
lipohypertrophy in children with type 1 diabetes, and to evaluate the associated factors.
Findings: 119 children coming for regular follow up in the diabetes clinic were examined for the presence of
lipohypertrophy by inspection and palpation. The last 4 readings of glycated hemoglobin (HbA1c) levels and other
factors that may affect lipohypertrophy were documented. RESULTS: The patient’s age ranged from 2 months to 21
years with a median of 10 years (inter-quartile range = 6). Lipohypertrophy occurred in 54.9% of patients, more
commonly in males (62.7%) vs. females (48.4%) (P = 0.074). Grade 1 lipohypertrophy occurred in 42.5% and grade 2
in 12.4%. Lipohypertrophy was related significantly to the dose of insulin units per kg of body weight (Odds ratio
[OR] = 16.4; 95% CI, 2.2 - 124.6; P = 0.007), the duration of diabetes, [OR] = 1.16; 95% CI, 1.05 - 1.32; P = 0.004)),
and the body mass index (BMI) [OR] = 1.68; 95% CI, 1.25 - 2.15; P = 0.006). The mean HbA1c levels of patients with
grade 1 and grade 2 lipohypertrophy did not differ from diabetics without lipohypertrophy (F = 0.178, P = 0.837)
Conclusions: The presence of lipohypertrophy was significantly associated with the duration of diabetes and the
body mass index. Children with lipohypertrophy needed a significantly higher dose of insulin units/kg of body
weight to achieve fair control compared to children without lipohypertrophy. Further studies are needed to
ascertain the clinical meaning of these findings.
Findings
Lipohypertrophy is a frequent problem in young patients
with type 1 diabetes, occurring in up to 50% of patients,
it may be associated with poor glycaemic control, [1]
Although a cause for these lesions is not known, the
predisposing conditions may be trauma to the skin and
subcutaneous tissue repeated over time in the presence
of insulin [2]. Histolgically the hypertrophic adipocytes
are twice as large as those from normal subcutaneous
areas and contained numerous small lipid droplets. Elec-
tron microscopic analysis also revealed a minor popula-
tion of small adipocytes, suggesting active differentiation
or proliferation [3]. The injection of insulin into a site
of lipohypertrophy may lead to erratic absorption of the
insulin, with the potential for poor glycaemic control
and unpredictable hypoglycaemia [4]. Despite the
important implications for diabetes control in insulin-
injecting patients, there is a dearth of information in
children about the subject. The aim of this study was to
evaluate the prevalence of lipohypertrophy in children
with type 1diabetes, to study parameters associated with
its development and to assess its effect on diabetes
control.
Methods
Patients were evaluated and examined for the presence
of lipohypertrophy at routine follow-up clinic visits at
the Diabetes Clinic for children at El-Chatby University
Children’s Hospital, Alexandria. (A free teaching hospi-
tal). Observation and palpation techniques were used in
assessing lipohypertrophy in these diabetics. Lipohyper-
trophy was graded as following: grade 0 = no changes;
grade 1 = visible hypertrophy of fat tissue but palpably
normal consistency; grade 2 = massive thickening of fat
tissue with firm consistency; and grade 3 = lipoatrophy
[2]. Their age, weight, height, adjusted body mass index,
duration of diabetes, HbA1c levels (average of the last 4
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daily injections, washing hands before injection, insulin
regimen, individuals giving the injection and education
of their mothers were documented. Patients and
mothers were asked how they rotate the injection sites.
Patients received human insulin from diabetes onset.
Most patients received a mixture of NPH and regular
insulin 30/70, only 7 received glargine insulin. Patients
were taught to rotate their injection sites every day
according to a scheme (left, right arm/left, right thigh
and/or left, right abdominal area). Data was analyzed
using the Statistical Package for the Social Sciences
(SPSS 14.0). Differences between the groups were calcu-
lated by the chi-square test for categorical variables,
ANOVA test for two or more continuous variables, and
logistic regression to obtain odds ratios for variables
with significant P-values. The study protocol was
approved by the institutional review board of the college
of medicine in Alexandria University (Egypt), and a
written parental consent and child assent were obtained
before the study.
Results
1. Prevalence of lipohypertrophy
The injection sites were examined in 119 children dur-
ing their regular visits to the diabetes clinic (64 female
and 55 male). Their ages ranged from 8 months to 21
years with a median of 10 years (inter-quartile range =
6). Prevalence of lipohypertrophy in patients injecting in
the arms was: no change in 45.1%, grade 1 lipohypertro-
phy in 42.5% and grade 2 lipohypertrophy in 12.4%
(table 1). The thighs were used for injecting in 63% of
children and showed no change in 76%, grade 1 lipohy-
pertrophy in 16% and grade 2 lipohypertrophy in 8%
(Table 1). The thighs were used less frequently as an
injection site, lipohypertrophy was not seen in the abdo-
men, as 83% of the patients were afraid to inject in the
abdomen. lipohypertrophy was not affected significantly
by rotation of the injection site (P = 0.74).
2. Factors associated with lipohypertrophy
About 69% of patients were using micro fine needle (8
mm length), Lipohypertrophy occured in 48.7% of them.
The pen was used in 13.3% of cases and lipohypertrophy
occurred in 73.45%, this was significant by chi-square
test (P = 0.043), but on doing logistic regression, the
Injection method was not associated significantly with
lipohypertrophy.
Percentile adjusted BMI was calculated and was found
that 76.1% of children were normal, 15.0% overweight,
3.5% obese and 5.3% were under weight. This finding
was significantly related to the occurrence of lipohyper-
trophy [OR] = 1.68; 95% CI, 1.25 - 2.15; P = 0.006.
(Table 2)
All Patients with grade, 1 and 2 lipohypertrophy had
HbA1c levels similar to patients without lipohypertrophy
as the mean was 8.4 ± 2.1, 8.8 ± 1.9, 8.5 ± 2.3 respec-
tively. This was not statistically significant (P = 0.837),
but lipohypertrophy was related significantly to the dose
of insulin units per kg of body weight as the mean was
0.75 ± 0.21 U/kg in patients without lipohypertrophy
versus 0.99 ± 0.52 U/kg in patients with grade 2 lipohy-
pertrophy [OR] = 16.4; 95% CI, 2.2 - 124.6; P = 0.007.
Lipohypertrophy was related also to the duration of dia-
betes, as the mean duration was 4.13 ± 3.67 years in
patients with grade 0 and 7.07 ± 2.841 years in grade 2
lipohypertrophy [OR] = 1.16; 95% CI, 1.05 - 1.32; P =
0.004. In one patient lipohypertrophy developed 6
months after the onset of diabetes.
Washing hands before injections, type of insulin, num-
ber of injections per day, the frequency of changing the
needle, the individual giving the injection, history of
atopy, and the degree of mother’s education, all did not
affect the occurrence of lipohypertrophy significantly
Discussion
Lipohypertrophy as a local complication of insulin ther-
apy is well recognized, it is the most common cutaneous
complication of insulin therapy, despite improvements
in insulin purity and the introduction of recombinant
human insulin its prevalence has remained high. The
importance of this complication is not only cosmetic
[5], but it also may impact on insulin absorption, and
therefore its effect on glycaemic control is not well
known.
In this study the prevalence of lipohypertrophy was
similar to other studies [1,2], it occurred more in the
arms, as the thighs were used less frequently as an injec-
tion site, children stated pain and bleeding after injec-
tion were the main reasons of not using the thighs,
Table 1 Prevalence of lipohypertrophy at different injection sites
Grade 0 Lipohypertrophy
(n = 51)
Grade1 Lipohypertrophy
(n = 48)
Grade2 Lipohypertrophy
(n = 14)
Total
(n = 113)
No % No % No % No
The arms 51 45.1 48 42.5 14 12.4 113
The thighs 57 76 12 16 6 8 75
The abdomen 14 100 0 0 0 0 14
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was mainly due to their young age. Lipohypertrophy in
our patients was not significantly affected by rotation of
the injection sites as many children without lipohyper-
trophy were not rotating injections sites despite repeated
advice. In one patient lipohypertrophy developed 6
months after the onset of diabetes and this may denote
that lipohypertrophy is not only caused by repeated
trauma to the skin but other unknown factors exist.
It was observed that patients with lipohypertrophy
needed a significantly higher dose of insulin units per kg
of their body weight compared to those without lipohy-
pertrophy, this could be due to defective absorption of
insulin by the abnormal injection sites [6] or the high
titre of insulin antibodies found in children with type 1
diabetes and lipohypertrophy [7]. It was concluded by
Overland J, et al, [8] that “the pharmacokinetic and
pharmacodynamic effect of injecting into lipohyper-
trophic tissue is small in comparison to the usual clini-
cal variation observed with insulin injections as there
was no difference in continuous glucose monitoring
(CGMS) profiles between areas with lipohypertrophy
and areas without lipohypertrophy. Therefore, the exact
effect of lipohypertrophy is still not clear. Lipohypertro-
phy was significantly less common in obese and over-
weight versus normal and underweight patients, similar
findings were observed by Conwell LS et al [9] but with
continuous subcutaneous insulin infusion, this may be
explained as in underweight and normal children the
areas of lipohypertrophy are more easily seen and felt
than in obese patients.
Conclusion
The presence of lipohypertrophy was significantly asso-
ciated with the duration of diabetes and the body mass
index. Children with lipohypertrophy needed a signifi-
cantly higher dose of insulin units/kg of body weight to
achieve fair control compared to children without lipo-
hypertrophy. Further studies are needed to ascertain the
clinical meaning of these findings.
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Table 2 Logistic regression for factors with a significant
P-value
B S.E. df P OR 95% C.I.
D.M Duration 0.15 0.06 1 0.004 1.16 1.05 - 1.32
BMI 0.52 0.05 1 0.006 1.68 1.25 - 2.15
Insulin units/kg 2.8 1.0 1 0.007 16.4 2.2 - 124.6
Constant -0.68 0.34 1 0.048 0.509
P value for the model = 0.004
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